Peritoneal oxygen / ozone insufflation (IPO3). Total remission of asthenia and pain in one terminal oncological patient after IPO3 cycle.

Abstract

Pain and asthenia are symptoms of difficult control in cancer patients and greatly determine their quality of life. Conventional ozone therapy is used successfully in the symptomatic control of patients with cancer. We believe that the administration of ozone at high doses through IPO3 could provide an additional benefit in the control of refractory symptoms in patients with cancer. 
 We present below a cancer patient with very deteriorated quality of life, successfully treated with IPO3. 
 The patient is a 48-year-old woman with a history of breast cancer who has a disseminated metastatic recurrence that affects bones, skull, liver, lung and peritoneum, with symptomatology refractory to symptomatic medication. Her quality of life was limited by severe asthenia (which kept her bedridden for more than two months) and pain refractory to symptomatic treatment with opiates and corticosteroids. 
 The patient was treated with a cycle of rectal ozone therapy, consisting of a conditioning cycle with 15 sessions of oxygen / ozone rectally, followed by placement of a peritoneal catheter to subsequently perform five IPO3 sessions.
 At the end of the treatment, all the symptoms of the patient were resolved completely, allowing the withdrawal of all the analgesic medication, returning the patient to a normal life. There were no side effects, and the beneficial effects of this IPO3 cycle were maintained for more than two months. The analysis showed diminution of the tumor and inflammatory markers during the treatment. 
 Ozone therapy at high doses should be considered in cancer patients with severe symptoms and refractory to conventional treatment.